
    
      A randomised, double-blind, double-dummy, 52-week, parallel group study of a standard dosing
      regimen with salmeterol/fluticasone propionate combination 50/250mcg bid (via the
      DISKUS/ACCUHALER inhaler) versus a symptom-driven variable dosing regimen with
      formoterol/budesonide combination 6/200mcg (via a breath-actuated dry powder reservoir
      inhaler)in adults asthmatics
    
  